{"id":"perindopril-moxonidine","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry cough"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Perindopril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Moxonidine is a selective imidazoline-1 receptor agonist that decreases central sympathetic nervous system activity. The combination provides synergistic antihypertensive effects targeting both the renin-angiotensin-aldosterone system and sympathetic nervous system.","oneSentence":"Perindopril inhibits ACE to reduce angiotensin II formation, while moxonidine activates central imidazoline receptors to reduce sympathetic outflow, together lowering blood pressure through complementary pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:35:51.674Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT02355821","phase":"NA","title":"Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women","status":"COMPLETED","sponsor":"National Research Center for Preventive Medicine","startDate":"2015-04","conditions":"Osteopenia, Arterial Hypertension","enrollment":114},{"nctId":"NCT04023565","phase":"PHASE4","title":"Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome","status":"UNKNOWN","sponsor":"Sergey V. Nedogoda","startDate":"2019-03-11","conditions":"Arterial Hypertension, Metabolic Syndrome","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"perindopril + moxonidine","genericName":"perindopril + moxonidine","companyName":"Sergey V. Nedogoda","companyId":"sergey-v-nedogoda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Perindopril inhibits ACE to reduce angiotensin II formation, while moxonidine activates central imidazoline receptors to reduce sympathetic outflow, together lowering blood pressure through complementary pathways. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}